Monte Rosa Therapeutics (GLUE) Other Working Capital Changes (2020 - 2026)

Monte Rosa Therapeutics' Other Working Capital Changes history runs 5 years deep, the most recent figure standing at -$434000.0 for Q1 2026.

• On a quarterly basis, Other Working Capital Changes fell 53.36% year-over-year to -$434000.0 in Q1 2026; TTM through Mar 2026 was -$1.2 million, a 6.03% decrease from a year earlier, with the FY2025 full-year figure at -$1.1 million, up 19.96% from the prior year.
• Other Working Capital Changes fell to -$434000.0 in Q1 2026 per GLUE's latest filing, from -$298000.0 in the prior quarter.
• Across five years, Other Working Capital Changes topped out at $110.2 million in Q3 2025 and bottomed at -$106.9 million in Q2 2025.
• The 5-year median for Other Working Capital Changes is $421500.0 (2022), against an average of $8.6 million.
• Across the five-year window, Other Working Capital Changes soared 1938.67% in 2023 and slumped 223.22% in 2024, its largest moves.
• Year by year, Other Working Capital Changes stood at -$163000.0 in 2022, then soared by 324.54% to $366000.0 in 2023, then slumped by 223.22% to -$451000.0 in 2024, then surged by 33.92% to -$298000.0 in 2025, then slumped by 45.64% to -$434000.0 in 2026.
• Per Business Quant, the three latest GLUE Other Working Capital Changes figures stand at -$434000.0 (Q1 2026), -$298000.0 (Q4 2025), and -$354000.0 (Q3 2025).